01753nas a2200361   4500000000100000008004100001653001600042653001500058653001600073653000900089653002800098653001100126653001900137653001100156653001100167653002500178653001600203653002100219653001000240653001000250653001500260100001400275700001400289700003300303700001300336700001400349245012000363856010600483300001400589490000700603520076700610022001401377       2019                            d10aYoung Adult10aPrevalence10aMiddle Aged10aMale10aLeishmaniasis, Visceral10aHumans10aHIV Infections10aFemale10aBrazil10aDisease Notification10aCoinfection10aChild, Preschool10aChild10aAdult10aAdolescent1 aSantos GO1 aJesus NPS1 aVasconcelos Cerqueira-Braz J1 aSantos V1 aLemos LMD00aPrevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil.  uhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822019000100623&lng=en&nrm=iso&tlng=en  ae201802570 v523 a<p><strong>INTRODUCTION: </strong>Cases of visceral leishmaniasis (VL) and HIV co-infection have increased worldwide. We investigated the prevalence of HIV and associated factors among VL patients in Sergipe state, Brazil.</p>

<p><strong>METHODS: </strong>We conducted a population-based study of all cases of VL and HIV reported in Sergipe from 1999 to 2015.</p>

<p><strong>RESULTS: </strong>We studied a total of 917 patients; 41 (4.5%) co-infection cases were detected. VL-HIV co-infected patients were more likely to have weight loss, cough, treatment failure or loss to follow-up and death.</p>

<p><strong>CONCLUSIONS: </strong>The prevalence of VL-HIV co-infection was high and co-infected patients were more likely to have adverse outcomes.</p>
  a1678-9849